Cardiovascular medication use following percutaneous coronary intervention: The Australian experience
Aims: Despite the guidelines, a "treatment gap" exists in the delivery of pharmacotherapy for secondary prevention. We aimed to analyze the trend in guideline-based medication usage following percutaneous coronary intervention (PCI) using the Melbourne Interventional Group (MIG) registry o...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Blackwell Publishing Ltd
2014
|
| Online Access: | http://hdl.handle.net/20.500.11937/44961 |
| _version_ | 1848757149790896128 |
|---|---|
| author | Cole, J. Brennan, A. Ajani, A. Yan, B. Duffy, S. Loane, P. Reid, Christopher Yudi, M. New, G. Black, A. Shaw, J. Clark, D. Andrianopoulos, N. |
| author_facet | Cole, J. Brennan, A. Ajani, A. Yan, B. Duffy, S. Loane, P. Reid, Christopher Yudi, M. New, G. Black, A. Shaw, J. Clark, D. Andrianopoulos, N. |
| author_sort | Cole, J. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Aims: Despite the guidelines, a "treatment gap" exists in the delivery of pharmacotherapy for secondary prevention. We aimed to analyze the trend in guideline-based medication usage following percutaneous coronary intervention (PCI) using the Melbourne Interventional Group (MIG) registry over a 6-year period (2005-2010). Methods: The MIG registry prospectively collects demographical, clinical, and procedural characteristics of consecutive patients undergoing PCI. We assessed medication use (aspirin, clopidogrel, ACE inhibitors, angiotensin receptor blockers, beta-blockers, and lipid-lowering agents) at 30 days and 12 months in patients alive and able to provide the information. Results: The cohort consists of 12,813 patients who underwent 14,787 consecutive interventional procedures. They comprised 76% males: 22% were elderly (=75 years), 23% had diabetes, 2% had severe renal impairment, 2% had severe left ventricular dysfunction, 26% presented with STEMI, and 44% of patients received drug-eluting stent. Follow-up was complete for 97.8% of the cohort at 30 days (2.2% mortality) and 89.1% at 12 months (4% mortality). From 2005 to 2010, the percentage of patients taking all five classes of medications increased each year. In 2010 at 30 days, nearly 60% of patients took all five classes of medications, and by 12 months, 75% of patients were taking four or five classes of medications. Conclusion: In conclusion, while the increasing use of cardiovascular medicines in an "at-risk" Australian cohort is encouraging, a treatment gap appears to still exist. |
| first_indexed | 2025-11-14T09:23:30Z |
| format | Journal Article |
| id | curtin-20.500.11937-44961 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:23:30Z |
| publishDate | 2014 |
| publisher | Blackwell Publishing Ltd |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-449612017-09-13T14:19:37Z Cardiovascular medication use following percutaneous coronary intervention: The Australian experience Cole, J. Brennan, A. Ajani, A. Yan, B. Duffy, S. Loane, P. Reid, Christopher Yudi, M. New, G. Black, A. Shaw, J. Clark, D. Andrianopoulos, N. Aims: Despite the guidelines, a "treatment gap" exists in the delivery of pharmacotherapy for secondary prevention. We aimed to analyze the trend in guideline-based medication usage following percutaneous coronary intervention (PCI) using the Melbourne Interventional Group (MIG) registry over a 6-year period (2005-2010). Methods: The MIG registry prospectively collects demographical, clinical, and procedural characteristics of consecutive patients undergoing PCI. We assessed medication use (aspirin, clopidogrel, ACE inhibitors, angiotensin receptor blockers, beta-blockers, and lipid-lowering agents) at 30 days and 12 months in patients alive and able to provide the information. Results: The cohort consists of 12,813 patients who underwent 14,787 consecutive interventional procedures. They comprised 76% males: 22% were elderly (=75 years), 23% had diabetes, 2% had severe renal impairment, 2% had severe left ventricular dysfunction, 26% presented with STEMI, and 44% of patients received drug-eluting stent. Follow-up was complete for 97.8% of the cohort at 30 days (2.2% mortality) and 89.1% at 12 months (4% mortality). From 2005 to 2010, the percentage of patients taking all five classes of medications increased each year. In 2010 at 30 days, nearly 60% of patients took all five classes of medications, and by 12 months, 75% of patients were taking four or five classes of medications. Conclusion: In conclusion, while the increasing use of cardiovascular medicines in an "at-risk" Australian cohort is encouraging, a treatment gap appears to still exist. 2014 Journal Article http://hdl.handle.net/20.500.11937/44961 10.1111/1755-5922.12060 Blackwell Publishing Ltd unknown |
| spellingShingle | Cole, J. Brennan, A. Ajani, A. Yan, B. Duffy, S. Loane, P. Reid, Christopher Yudi, M. New, G. Black, A. Shaw, J. Clark, D. Andrianopoulos, N. Cardiovascular medication use following percutaneous coronary intervention: The Australian experience |
| title | Cardiovascular medication use following percutaneous coronary intervention: The Australian experience |
| title_full | Cardiovascular medication use following percutaneous coronary intervention: The Australian experience |
| title_fullStr | Cardiovascular medication use following percutaneous coronary intervention: The Australian experience |
| title_full_unstemmed | Cardiovascular medication use following percutaneous coronary intervention: The Australian experience |
| title_short | Cardiovascular medication use following percutaneous coronary intervention: The Australian experience |
| title_sort | cardiovascular medication use following percutaneous coronary intervention: the australian experience |
| url | http://hdl.handle.net/20.500.11937/44961 |